Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBITDA (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EBITDA for 8 consecutive years, with -$17.6 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 41.15% to -$17.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$15.5 million, a 74.82% increase, with the full-year FY2024 number at -$63.7 million, up 2.93% from a year prior.
  • EBITDA was -$17.6 million for Q3 2025 at Whitehawk Therapeutics, up from -$52.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $73.0 million in Q1 2025 to a low of -$86.9 million in Q3 2021.
  • A 5-year average of -$15.7 million and a median of -$16.2 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 1383.11% in 2021, then skyrocketed 498.39% in 2025.
  • Whitehawk Therapeutics' EBITDA stood at -$16.6 million in 2021, then increased by 16.28% to -$13.9 million in 2022, then decreased by 16.49% to -$16.2 million in 2023, then fell by 12.76% to -$18.3 million in 2024, then rose by 3.72% to -$17.6 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's EBITDA are -$17.6 million (Q3 2025), -$52.6 million (Q2 2025), and $73.0 million (Q1 2025).